My Blue Dots

HAYWARD, Calif.–(BUSINESS WIRE)– #CancerTherapy–RefleXion® Medical, an external-beam theranostic oncology company, today announced initiation of the BIOGUIDE-X2 clinical study to expand indications for SCINTIX® biology-guided radiotherapy at Hackensack Meridian John Theurer Cancer Center, a research partner with Georgetown’s Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center. The company also announced key updates from the Centers for Medicare and Medicaid (CMS) Services. Sta

PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of approximately $200 million, an increase of 29% Reported approximately 57,300 oncology clinical tests (excluding Shield

NIJMEGEN, Niederlande–(BUSINESS WIRE)–Aiosyn, ein Pionier im Bereich KI-gestützter Pathologiesoftware für Krebs- und Nierenerkrankungen, hat bekannt gegeben, dass sein Algorithmus zur Zählung mitotischer Figuren die CE-Kennzeichnung gemäß der In-Vitro-Diagnostik-Verordnung (IVDR) für den Einsatz in der Diagnostik erhalten hat. Dieser Meilenstein etabliert Aiosyn Mitosis Breast als erste IVDR-zertifizierte Anwendung für die Mitosenzählung in der Brustkrebsdiagnostik und beschleunigt das Wachst

LONDON–(BUSINESS WIRE)–VitVio raises $2 million in pre-seed funding from LDV Capital, Bek Ventures (ex-Earlybird) and TSIC to bring AI to operating rooms at top UK hospital.

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 6, 2025, to three non-executive employees of non-qualified stock option

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San Francisco, CA. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutic

BURLINGTON, Mass.–(BUSINESS WIRE)–Please replace the release dated January 6, 2025, with the following corrected version due to multiple revisions. The updated release reads: PHARMAESSENTIA ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FROM SURPASS-ET STUDY EVALUATING ROPEGINTERFERON ALFA-2B-NJFT (P1101) FOR ESSENTIAL THROMBOCYTHEMIA SURPASS-ET trial achieved its primary endpoint, demonstrating a durable response in 42.9% of participants in the P1101 group versus 6.0% in the comparator group (p=0.0